XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company based in Herzliya, Israel, focused on acquiring and developing drugs for autoimmune diseases. Its lead candidate, hCDR1, is a Phase II-ready asset for systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 across various indications. Incorporated in 1993, it was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.